SynthesisCardiovascular drugs and therapy2026
Gut Microbiota and Its Metabolites in the Prognosis of Coronary Heart Disease: A Systematic Review and Mechanistic Insights.
Synthesis in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeEmerging evidence links gut microbiota dysbiosis and its metabolites to atherosclerosis. This systematic review aims to synthesize prospective evidence on the association of gut microbiota and its metabolites with prognosis in coronary heart disease (CHD) patients.
methodsA systematic search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted from inception to January 21, 2026. Prospective cohort studies, nested case-control studies, or prospective case-control studies reporting associations between gut microbiota features or metabolite levels and major adverse cardiovascular and cerebrovascular events (MACCE, including all-cause death, cardiovascular death, myocardial infarction, stroke, unstable angina, heart failure, and all-cause unplanned hospitalization/emergency department visits) in CHD patients were included.
resultsEighteen studies were included. Higher Lactobacillus abundance was associated with favorable prognosis, whereas a 10-species microbial risk score (MRS) predicted increased MACCE risk. For microbial metabolites, elevated trimethylamine N-oxide (TMAO) showed a consistent concentration-response association with increased MACCE risk. Phenylacetylglutamine (PAGln) and imidazole propionate (ImP) independently predicted poor outcomes in STEMI patients. Indole-3-propionic acid (IPA) was associated with reduced mortality, whereas deoxycholic acid (DCA) was associated with increased risk, while indoxyl sulfate (IS), acylcarnitines, and choline predicted worse outcomes. Mechanistically, these metabolites modulate inflammation, lipid metabolism, endothelial function, and platelet activation.
conclusionsGut microbial features, particularly Lactobacillus abundance, are associated with favorable prognosis, whereas specific microbial risk patterns predict increased risk. Metabolites TMAO, PAGln, and ImP are linked to poor outcomes, while IPA may confer protection and DCA is associated with increased risk. These findings not only provide new insights into the pathogenesis of coronary heart disease but also identify potential therapeutic targets for microbiota-based interventions.
Indexed as
Identifiers
42853538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.